INS and type 2 diabetes mellitus: The rationale for such treatment may be provided by the blunted response to GIP-stimulated insulin release in humans with T2DM, its anorexigenic effect, and its possible impact on the reduction of lipogenesis and increase in lipolysis [152,158,159,160].